Longitude Prize on ALS

About

The Longitude Prize on ALS invites innovative teams to leverage AI in drug discovery for ALS, with a total prize fund of £7.5 million, including substantial funding at each stage of the competition, aimed at accelerating breakthroughs in treatment for this challenging disease.

Benefits

• £7.5 million prize fund available
• £100,000 awarded to 20 teams in Stage 1
• £200,000 awarded to 10 teams in Stage 2
• £500,000 awarded to 5 teams in Stage 3
• £1,000,000 for the winning team

Eligibility Criteria

• Open to teams using AI-based approaches for drug discovery
• Focus on amyotrophic lateral sclerosis (ALS) solutions
• Global participation encouraged